Skip to main content

Illumina Value Stock - Dividend - Research Selection


ISIN: US4523271090, WKN: 927079

Market price date: 17.05.2022
Market price: 243,22 USD

Illumina Fundamental data and company key figures of the share

Annual reports in USD
Key figures 13-02-2022
Cash flow
Net operating cash flow 545.000.000
Capital Expenditures -208.000.000
Free cash flow 337.000.000
Balance sheet
Total Equity 10.740.000.000
Liabilities & Shareholders equity
Income statement
Net income 762.000.000
Eps (diluted) 5,040
Diluted shares outstanding 153.000.000
Net sales/revenue 4.526.000.000

Fundamental ratios calculated on: 17-05-2022

Key figures 17-05-2022
Cash flow
P/C 68,28
P/FC 110,42
Balance sheet
Income statement
Div. Yield0,00%

Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.

Market Capitalization37.212.659.712,00 USD
CountryUnited States
IndicesMSCI World Index,NASDAQ 100,NASDAQ Comp.,S&P 500
SectorsLife Sciences Tools & Services
Raw Data SourceUS GAAP in Millionen USD
Stock Split2008-09-24,2.0000/1.0000; 2008-09-23,2.0000/1.0000

Description of the company

Illumina, Inc. (Illumina) is a developer and manufacturer of life science tools and integrated systems for the analysis of genetic variation and function. Illumina provides a line of genetic analysis solutions, with products and services that serve a range of interconnected markets, including sequencing, genotyping, gene expression, and molecular diagnostics. The Company is organized in two business segments: Life Sciences and Diagnostics. Its Life Sciences business unit includes all products and services related to the research market, namely the product lines based on its sequencing, BeadArray, VeraCode, and real-time PCR technologies. Its Diagnostics business unit focuses on molecular diagnostics. Its customers include genomic research centers, academic institutions, government laboratories, and clinical research organizations. In February 2013, it completed the acquisition of Verinata Health, Inc. Effective July 23, 2013, Illumina Inc acquired Advanced Liquid Logic Inc.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources::,,


GRAIL and Intermountain Healthcare Expand Partnership to Offer Galleri® Multi-Cancer Early Detection Blood Test to Eligible Patients in Utah

MENLO PARK, Calif. & SALT LAKE CITY, May 17, 2022--Intermountain Healthcare will offer Galleri®, GRAIL's multi-cancer early detection blood test, as a complement to existing single cancer screenings.

SEC filings reveal massive selling in media names, including Disney and Comcast

Leslie Picker joins the 'Halftime Report' to discuss what to expect from the SEC 13-F filings.

Top 5 1st Quarter Trades of Iron Triangle Partners LP


Is Illumina, Inc.'s (NASDAQ:ILMN) Recent Price Movement Underpinned By Its Weak Fundamentals?

With its stock down 31% over the past month, it is easy to disregard Illumina (NASDAQ:ILMN). We, however decided to...

Illumina price target lowered to $360 from $460 at Piper Sandler

Piper Sandler analyst Dav... ILMN

These 5-Stock Samplers Have Gotten Whacked. And That's OK

Our track record with 5-Stock Samplers has been simply astounding. So many times we've crushed the market! But remember when we said it wouldn't always be that way? That to win we sometimes have to lose? This is that time, Fools.

Comprehensive Study Establishes Cost of Late Detection and Treatment of Cancer

Cancer is the second leading cause of death and cancer care costs $1 trillion annually.

July 1st Options Now Available For Illumina (ILMN)

Staff article entitled July 1st Options Now Available For Illumina (ILMN), about stock options, from Stock Options Channel.

Top 5 1st Quarter Trades of Geo Capital Gestora de Recursos Ltd


Illumina Partners With Allelica, Inc.

Partnership aims to provide better understanding of common disease risk prediction through their Polygenic Risk Score (PRS) software suite